Hypereosinophilic syndrome : a multicenter, retrospective analysis of clinical characteristics and response to therapy
BACKGROUND: Hypereosinophilic syndrome (HES) is a heterogeneous group of rare disorders defined by persistent blood eosinophilia > or =1.5 x 10(9)/L, absence of a secondary cause, and evidence of eosinophil-associated pathology. With the exception of a recent multicenter trial of mepolizumab (anti-IL-5 mAb), published therapeutic experience has been restricted to case reports and small case series.
OBJECTIVE: The purpose of the study was to collect and summarize baseline demographic, clinical, and laboratory characteristics in a large, diverse cohort of patients with HES and to review responses to treatment with conventional and novel therapies.
METHODS: Clinical and laboratory data from 188 patients with HES, seen between January 2001 and December 2006 at 11 institutions in the United States and Europe, were collected retrospectively by chart review.
RESULTS: Eighteen of 161 patients (11%) tested were Fip1-like 1-platelet-derived growth factor receptor alpha (FIP1L1-PDGFRA) mutation-positive, and 29 of 168 patients tested (17%) had a demonstrable aberrant or clonal T-cell population. Corticosteroid monotherapy induced complete or partial responses at 1 month in 85% (120/141) of patients with most remaining on maintenance doses (median, 10 mg prednisone equivalent daily for 2 months to 20 years). Hydroxyurea and IFN-alpha (used in 64 and 46 patients, respectively) were also effective, but their use was limited by toxicity. Imatinib (used in 68 patients) was more effective in patients with the FIP1L1-PDGFRA mutation (88%) than in those without (23%; P < .001).
CONCLUSION: This study, the largest clinical analysis of patients with HES to date, not only provides useful information for clinicians but also should stimulate prospective trials to optimize treatment of HES.
| Errataetall: |
CommentIn: J Allergy Clin Immunol. 2010 Jun;125(6):1399-1401.e2. - PMID 20392489 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2009 |
|---|---|
| Erschienen: |
2009 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:124 |
|---|---|
| Enthalten in: |
The Journal of allergy and clinical immunology - 124(2009), 6 vom: 01. Dez., Seite 1319-25.e3 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ogbogu, Princess U [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 12.01.2010 Date Revised 21.03.2022 published: Print CommentIn: J Allergy Clin Immunol. 2010 Jun;125(6):1399-1401.e2. - PMID 20392489 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jaci.2009.09.022 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM192797840 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM192797840 | ||
| 003 | DE-627 | ||
| 005 | 20231223193633.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231223s2009 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jaci.2009.09.022 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0643.xml |
| 035 | |a (DE-627)NLM192797840 | ||
| 035 | |a (NLM)19910029 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ogbogu, Princess U |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hypereosinophilic syndrome |b a multicenter, retrospective analysis of clinical characteristics and response to therapy |
| 264 | 1 | |c 2009 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.01.2010 | ||
| 500 | |a Date Revised 21.03.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentIn: J Allergy Clin Immunol. 2010 Jun;125(6):1399-1401.e2. - PMID 20392489 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: Hypereosinophilic syndrome (HES) is a heterogeneous group of rare disorders defined by persistent blood eosinophilia > or =1.5 x 10(9)/L, absence of a secondary cause, and evidence of eosinophil-associated pathology. With the exception of a recent multicenter trial of mepolizumab (anti-IL-5 mAb), published therapeutic experience has been restricted to case reports and small case series | ||
| 520 | |a OBJECTIVE: The purpose of the study was to collect and summarize baseline demographic, clinical, and laboratory characteristics in a large, diverse cohort of patients with HES and to review responses to treatment with conventional and novel therapies | ||
| 520 | |a METHODS: Clinical and laboratory data from 188 patients with HES, seen between January 2001 and December 2006 at 11 institutions in the United States and Europe, were collected retrospectively by chart review | ||
| 520 | |a RESULTS: Eighteen of 161 patients (11%) tested were Fip1-like 1-platelet-derived growth factor receptor alpha (FIP1L1-PDGFRA) mutation-positive, and 29 of 168 patients tested (17%) had a demonstrable aberrant or clonal T-cell population. Corticosteroid monotherapy induced complete or partial responses at 1 month in 85% (120/141) of patients with most remaining on maintenance doses (median, 10 mg prednisone equivalent daily for 2 months to 20 years). Hydroxyurea and IFN-alpha (used in 64 and 46 patients, respectively) were also effective, but their use was limited by toxicity. Imatinib (used in 68 patients) was more effective in patients with the FIP1L1-PDGFRA mutation (88%) than in those without (23%; P < .001) | ||
| 520 | |a CONCLUSION: This study, the largest clinical analysis of patients with HES to date, not only provides useful information for clinicians but also should stimulate prospective trials to optimize treatment of HES | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, N.I.H., Intramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Adrenal Cortex Hormones |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Benzamides |2 NLM | |
| 650 | 7 | |a CCL17 protein, human |2 NLM | |
| 650 | 7 | |a Chemokine CCL17 |2 NLM | |
| 650 | 7 | |a IL5 protein, human |2 NLM | |
| 650 | 7 | |a Interferon-alpha |2 NLM | |
| 650 | 7 | |a Interleukin-5 |2 NLM | |
| 650 | 7 | |a Oncogene Proteins, Fusion |2 NLM | |
| 650 | 7 | |a Piperazines |2 NLM | |
| 650 | 7 | |a Pyrimidines |2 NLM | |
| 650 | 7 | |a mRNA Cleavage and Polyadenylation Factors |2 NLM | |
| 650 | 7 | |a reslizumab |2 NLM | |
| 650 | 7 | |a 35A26E427H |2 NLM | |
| 650 | 7 | |a Cyclosporine |2 NLM | |
| 650 | 7 | |a 83HN0GTJ6D |2 NLM | |
| 650 | 7 | |a Imatinib Mesylate |2 NLM | |
| 650 | 7 | |a 8A1O1M485B |2 NLM | |
| 650 | 7 | |a mepolizumab |2 NLM | |
| 650 | 7 | |a 90Z2UF0E52 |2 NLM | |
| 650 | 7 | |a FIP1L1-PDGFRA fusion protein, human |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a Receptor, Platelet-Derived Growth Factor alpha |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a Tryptases |2 NLM | |
| 650 | 7 | |a EC 3.4.21.59 |2 NLM | |
| 650 | 7 | |a Hydroxyurea |2 NLM | |
| 650 | 7 | |a X6Q56QN5QC |2 NLM | |
| 700 | 1 | |a Bochner, Bruce S |e verfasserin |4 aut | |
| 700 | 1 | |a Butterfield, Joseph H |e verfasserin |4 aut | |
| 700 | 1 | |a Gleich, Gerald J |e verfasserin |4 aut | |
| 700 | 1 | |a Huss-Marp, Johannes |e verfasserin |4 aut | |
| 700 | 1 | |a Kahn, Jean Emmanuel |e verfasserin |4 aut | |
| 700 | 1 | |a Leiferman, Kristin M |e verfasserin |4 aut | |
| 700 | 1 | |a Nutman, Thomas B |e verfasserin |4 aut | |
| 700 | 1 | |a Pfab, Florian |e verfasserin |4 aut | |
| 700 | 1 | |a Ring, Johannes |e verfasserin |4 aut | |
| 700 | 1 | |a Rothenberg, Marc E |e verfasserin |4 aut | |
| 700 | 1 | |a Roufosse, Florence |e verfasserin |4 aut | |
| 700 | 1 | |a Sajous, Marie-Helene |e verfasserin |4 aut | |
| 700 | 1 | |a Sheikh, Javed |e verfasserin |4 aut | |
| 700 | 1 | |a Simon, Dagmar |e verfasserin |4 aut | |
| 700 | 1 | |a Simon, Hans-Uwe |e verfasserin |4 aut | |
| 700 | 1 | |a Stein, Miguel L |e verfasserin |4 aut | |
| 700 | 1 | |a Wardlaw, Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a Weller, Peter F |e verfasserin |4 aut | |
| 700 | 1 | |a Klion, Amy D |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of allergy and clinical immunology |d 1971 |g 124(2009), 6 vom: 01. Dez., Seite 1319-25.e3 |w (DE-627)NLM000018449 |x 1097-6825 |7 nnns |
| 773 | 1 | 8 | |g volume:124 |g year:2009 |g number:6 |g day:01 |g month:12 |g pages:1319-25.e3 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jaci.2009.09.022 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 124 |j 2009 |e 6 |b 01 |c 12 |h 1319-25.e3 | ||